Suppr超能文献

正常人和法布里病患者血浆中中性糖鞘脂的代谢

Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease.

作者信息

Vance D E, Krivit W, Sweeley C C

出版信息

J Biol Chem. 1975 Oct 25;250(20):8119-25.

PMID:809441
Abstract

[6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease. The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives. Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%. The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period. During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete. A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began. The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began. In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%). The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled. The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%). Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day.

摘要

[6-2H₂]葡萄糖被用作示踪剂,用于对一名对照受试者和一名法布里病患者血浆中中性糖基神经酰胺的代谢进行比较研究。通过对四-O-乙酰甲基糖苷衍生物进行气相色谱-质谱分析,测定示踪剂掺入糖鞘脂的葡萄糖基和半乳糖基部分的情况。对样品中[6,6-2H₂]己糖测量的精密度和准确度实验表明,当掺入0.2%或更多的[6,6-2H₂]葡萄糖时,可在95%置信限为±0.16%的情况下检测到。将标记底物(35克)以5克的首剂量注入每个受试者体内,其余部分在10小时内以3克/小时的恒定速率给药。在输注过程中,每个受试者的血浆葡萄糖达到约30%[6,6-2H₂]葡萄糖的浓度,在底物给药完成后迅速下降。在输注开始后48至72小时之间,两名受试者血浆中的葡糖神经酰胺(GL-1a)中观察到0.8%[6,6-2H₂]葡萄糖的浓度。该脂质中的标记物以对数速率消失,在实验开始9天后,0.2%或更少的分子被标记。与GL-1a的结果相反,法布里病患者中[6,6-2H₂]己糖掺入乳糖神经酰胺(半乳糖基-(β1→4)-葡糖神经酰胺)的最大量(1.6%)是对照受试者(0.8%)的2倍。对照受试者血浆中的三己糖神经酰胺(半乳糖基-(α1→4)-半乳糖基-(β1→4)-葡糖神经酰胺,GL-3a)在葡萄糖基和半乳糖基部分的[6,6-2H₂]己糖含量最高达到0.4%,而法布里病患者的GL-3a未被显著标记。与对照受试者(0.7%)相比,法布里病患者中GL-4a部分(N-乙酰半乳糖胺基-半乳糖基-半乳糖基-葡糖神经酰胺)的最大标记量略有降低(0.4%)。计算出血浆糖鞘脂的周转时间为4至8天,周转率为1至6微摩尔/天。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验